Drug Trial Radar · NCT07713290
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Apr 3, 2025
Primary completion
Nov 12, 2026
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Beijing Gene Key Life Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.
Conditions
- Hepatocellular Carcinoma (HCC)
- Unresectable Hepatocellular Cancer
Interventions
GKL-006 InjectionDrug
An iNKT cell therapy
Transarterial chemoembolization (TACE)Procedure
A standard locoregional therapy for hepatocellular carcinoma
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment-Related Adverse Events and Safety/Tolerability RisksTime frame: From the start of study treatment through 14 days after the fourth treatment; treatment-related adverse events will continue to be assessed according to the study protocol.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing You An Hospital
Beijing, Beijing Municipality, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.